Insider Selling: Orthofix Medical Inc. (NASDAQ:OFIX) CEO Sells 9,203 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) CEO Massimo Calafiore sold 9,203 shares of the firm's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $17.14, for a total transaction of $157,739.42. Following the completion of the transaction, the chief executive officer now directly owns 124,151 shares in the company, valued at approximately $2,127,948.14. This represents a 6.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Massimo Calafiore also recently made the following trade(s):

• On Friday, January 10th, Massimo Calafiore sold 10,078 shares of Orthofix Medical stock. The shares were sold at an average price of $16.83, for a total transaction of $169,612.74.

Orthofix Medical Price Performance

Shares of OFIX traded up $0.14 during mid-day trading on Tuesday, hitting $17.51. The company's stock had a trading volume of 310,639 shares, compared to its average volume of 281,380. The firm has a 50-day moving average price of $18.17 and a 200 day moving average price of $16.72. The stock has a market capitalization of $669.13 million, a price-to-earnings ratio of -5.59 and a beta of 1.10. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. Orthofix Medical Inc. has a fifty-two week low of $12.08 and a fifty-two week high of $20.73.

Analyst Ratings Changes

A number of equities analysts have recently commented on OFIX shares. Stifel Nicolaus raised shares of Orthofix Medical from a "hold" rating to a "buy" rating and raised their target price for the company from $18.00 to $24.00 in a research note on Friday, November 8th. Roth Mkm reaffirmed a "buy" rating and set a $22.00 price target (up from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $23.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in OFIX. Quest Partners LLC purchased a new position in shares of Orthofix Medical in the second quarter worth approximately $64,000. Arizona State Retirement System purchased a new position in shares of Orthofix Medical in the second quarter worth approximately $139,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Orthofix Medical by 5.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,994 shares of the medical device company's stock worth $156,000 after acquiring an additional 559 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Orthofix Medical in the second quarter worth approximately $175,000. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Orthofix Medical in the third quarter worth approximately $216,000. 89.76% of the stock is owned by hedge funds and other institutional investors.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.